Aptose Voluntarily Suspends Clinical Dosing of APTO-253 to Review Drug Manufacturing Processes and Procedures

[frothmouth]

“ptose Biosciences Inc. (APTO) (APS.TO) (Aptose or the Company), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that the Food and Drug Administration (FDA), following a voluntary suspension of dosing b